Innovent Biologics of Suzhou has begun a US Phase I trial of its anti-CD47 mAb candidate (IBI188) in patients with advanced malignant tumors. By binding to the CD47 antigen on tumor cells, IBI188 is expected to block the CD47-SIRPα signaling...
Read moreAbbisko Therapeutics of Shanghai completed a $42 million series B fundraising led by new investor Qiming, which it will use to start clinical trials of its oncology molecules and expand its discovery pipeline. Later this year, the company expects...
Read moreChina is currently in the middle of a “Cambrian Explosion” of new drugs, according to Franck Le Deu, Senior Partner and Head of Greater China Healthcare practice at McKinsey & Company. The Cambrian Explosion is the period in...
Read moreUK-based Exscientia signed a three-year artificial intelligence (AI)-based drug discovery collaboration with Celgene. As part of the deal, Celgene is paying Exscientia $25 million upfront as well as various undisclosed milestone payments...
Read moreSTA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Beta Pharma, a biotech company focusing on innovative drug discovery and development in oncology, announce a strategic partnership. Under the terms of the collaboration...
Read moreGuangzhou Xiangxue Life Sciences (XLifeSc), a subsidiary of Xiangxue Pharmaceutical, was approved by China’s NMPA to start clinical studies of its T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy in patients with solid...
Read moreWuxi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received EMA GMP...
Read moreCellular Biomedicine Group Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it intends to...
Read moreGenoImmune, a subsidiary of Shenzhen sequencing company BGI, raised $18 million in an A funding round to support its neoantigen discovery for new immunotherapy candidates. The company has developed a service package to detect neoantigens by...
Read moreTianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas. Its Ebola vaccine has been...
Read moreCanada will create a national drug agency to help cut the cost of prescription medications as part of a plan to broaden the state-funded healthcare program, the finance ministry said in its budget on Tuesday. Unlike other countries with universal...
Read moreI-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, today announced dosing of the first healthy subject in a...
Read more
